首页 | 本学科首页   官方微博 | 高级检索  
     

卵巢癌的靶向药物治疗研究进展
引用本文:吴慧芳 王海琳. 卵巢癌的靶向药物治疗研究进展[J]. 现代生物医学进展, 2012, 12(6): 1195-1197
作者姓名:吴慧芳 王海琳
作者单位:1. 兰州大学第一临床医学院 甘肃兰州73000
2. 甘肃省人民医院 甘肃兰州73000
摘    要:
卵巢癌死亡率居女性生殖系统恶性肿瘤之首,早期诊断困难,晚期患者治疗效果差,分子靶向药物成为近年的研究热点。目前许多靶向药物已经进入临床试验阶段,给卵巢癌特别是术后复发及化疗耐药患者的治疗带来新的希望。本文主要对单克隆抗体,酪氨酸激酶抑制剂等几种药物在卵巢癌的研究进行综述。

关 键 词:卵巢癌  靶向药物  治疗

Targeted Drug in Ovarian Cancer
WU Hui-fang,WANG Hai-lin. Targeted Drug in Ovarian Cancer[J]. Progress in Modern Biomedicine, 2012, 12(6): 1195-1197
Authors:WU Hui-fang  WANG Hai-lin
Affiliation:1 First Clinical Medical College of LanZhou University LanZhou,GanSu 730000,China; 2 Department of Obstetrics and Gynecology,The People’s Hospital of GanSu Province LanZhou,GanSu 730000,China)
Abstract:
Ovarian cancer is the first leading cause of death among gynecologic malignancies.It is difficult to diagnose early and often had bad therapeutic effect at later period.So molecule targeted drug becomes the focus in recent years of research.At present,many molecule targeted drugs has been gaining interest and already made impressive progress in both the pre-clinical and clinical settings,bring new hopes for patients with ovarian cancer,especially for patients with recurrent and chemotherapy resistant cancers.This paper mainly reviews the recent achievements in the development of Monoclonal Antibodies and tyrosine kinase inhibitor for ovarian cancer therapy.
Keywords:Ovarian cancer  Targeted Drug  Therapy
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号